Show simple item record

dc.contributor.authorMoriarty, Niamh
dc.contributor.authorDowd, Eilís
dc.date.accessioned2019-03-20T15:05:45Z
dc.date.available2019-03-20T15:05:45Z
dc.date.issued2018-07-13
dc.identifier.citationMoriarty, Niamh, & Dowd, Eilís. (2018). Brain repair for Parkinson’s disease: is the answer in the matrix? Neural Regeneration Research, 13(7), 1187-1188. doi: 10.4103/1673-5374.235027en_IE
dc.identifier.issn1876-7958
dc.identifier.urihttp://hdl.handle.net/10379/15035
dc.description.abstractTwo hundred years after James Parkinson first described the cardinal motor symptoms of the disorder that would later bear his name, there is still an irrefutable need for a therapy that targets the underlying pathophysiology of the disease and not solely its symptoms. Parkinson’s disease (PD) is classically characterised by Lewy body formation and a relatively selective degeneration of nigrostriatal dopaminergic neurons (Schapira and Jenner, 2011). The loss of dopaminergic neurons from the substantia nigra pars compacta causes a consequential depletion of the neurotransmitter dopamine from the striatum, and it is this loss that causes the motor symptoms experienced by patients. To date, all treatments for this condition are symptomatic in that they simply endeavour to correct the neurochemical and/or electrical anomalies caused by striatal dopaminergic deafferentation in an attempt to improve motor function (LeWitt and Fahn, 2016). While such symptomatic approaches show extraordinary efficacy in the early years after initiating treatment, the underlying disease pathology continues to progress, and eventually their efficacy subsides. In view of this, there remains an urgent need for an alternative treatment approach that is capable of protecting or repairing the brain in order to provide a more sustained benefit to patients.en_IE
dc.description.sponsorshipOur research in this field is supported by the European Union Horizon 2020 Programme (H2020-MSCA-ITN-2015) under the Marie Sklodowska-Curie Innovative Training Networks and Grant Agreement No. 676408, Science Foundation Ireland (11/RFP/NES/3183), and through a postgraduate scholarship from the Irish Research Council to Niamh Moriarty.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherMedknow Publicationsen_IE
dc.relation.ispartofNeural Regeneration Researchen
dc.subjectTRANSPLANTATIONen_IE
dc.subjectSURVIVALen_IE
dc.subjectDELIVERYen_IE
dc.subjectFUTUREen_IE
dc.titleBrain repair for Parkinson's disease: is the answer in the matrix?en_IE
dc.typeArticleen_IE
dc.date.updated2019-03-15T14:53:14Z
dc.identifier.doi10.4103/1673-5374.235027
dc.local.publishedsourcehttps://dx.doi.org/10.4103/1673-5374.235027en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funderHorizon 2020en_IE
dc.contributor.funderScience Foundation Irelanden_IE
dc.internal.rssid14723789
dc.local.contactEilís Dowd, Dept Of Pharmacology, Nui, Galway.. 2776 Email: eilis.dowd@nuigalway.ie
dc.local.copyrightcheckedYes
dc.local.versionACCEPTED
dcterms.projectinfo:eu-repo/grantAgreement/EC/H2020::MSCA-ITN-ETN/676408/EU/Development of Biomaterial-based Delivery Systems for Parkinson’s disease - an Integrated Pan-European Approach/BrainMatTrainen_IE
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Frontiers Programme (RFP)/11/RFP.1/NES/3183/IE/Harnessing Adult Stem Cells for Neurotrophin Delivery to the Degenerating Brain/en_IE
nui.item.downloads56


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record